Filing identity and period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2020, filed May 11, 2020. This conflicts with the request metadata identifying “Solana Co”; the filing itself does not identify Solana Co. Financial amounts below are in U.S. dollars, generally thousands unless stated otherwise.
Business context
Helius is a neurotechnology company developing the PoNS non-invasive medical device. PoNS was authorized for sale in Canada for specified mild-to-moderate traumatic brain injury (mmTBI) treatment; Health Canada expanded authorization to include gait deficit associated with mild and moderate multiple sclerosis (MS) on March 18, 2020. The device remained investigational in the United States, European Union and Australia; the Australian application was under review. Canadian commercialization was the company’s principal source of revenue.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | $207 | $677; down $470 (69%) |
| Gross profit / margin | $106 / 51.2% | $441 / 65.1% |
| Operating expenses | $4,108 | $7,262 |
| Operating loss | $(4,002) | $(6,821) |
| Net income (loss) | $(4,757) | $1,324 |
| Basic and diluted loss per share | $(0.15) | Basic income per share $0.05; diluted loss per share $(0.06) |
| Net cash used in operating activities | $(3,751) | $(6,800) |
| Cash at period end | $4,360 | $5,459 at Dec. 31, 2019 |
| Working capital | $3,258 | $3,444 at Dec. 31, 2019 |
Cash used in investing activities was $10; financing provided $2,652, principally from equity sales. Total assets were $8,461 and total liabilities $3,252 at quarter end. The balance sheet lists no borrowings; operating lease liabilities totaled $597 ($180 current and $417 non-current). The company reported $321 current and $218 non-current deferred revenue.
Changes and notable items
- Revenue fell 69%, primarily reflecting lower PoNS product sales; 2020 included $9 of clinic-related fee revenue and $7 of license revenue. Q1 2019 product sales also included support-service activity that was no longer part of the same arrangement.
- Operating expenses decreased $3,154 year over year, including lower R&D and selling, general and administrative spending. R&D fell to $1,120 from $2,681; SG&A fell to $2,862 from $4,581. The company cited completed device development, lower staffing and reduced commercial spending; 2020 SG&A included a $174 intangible-asset impairment.
- The 2019 net profit included an $8,289 non-cash gain from the change in fair value of derivative instruments; the comparable 2020 gain was only $4. Q1 2020 also included a $765 foreign-exchange loss, compared with $155 in Q1 2019.
- Goodwill declined to $686 from $1,242 after acquisition fair-value adjustments and currency translation. A COVID-19-triggered quantitative test found no goodwill impairment, although customer-relationship intangibles incurred a $174 impairment.
- Cash declined by $1,099 during the quarter. The company raised $2,992 gross through its ATM program and March 2020 offering, before $340 of share issuance costs. The March offering issued 6,257,144 shares at $0.35 and warrants for an additional 6,257,144 shares at $0.46; the ATM sold 1,065,968 shares. Outstanding common shares increased to 38,041,666 from 30,718,554 at year-end.
Outlook, risks and contingencies
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after filing. It expected continuing operating losses and cash outflows, and said existing resources were expected to fund operations only through Q2 2020. Additional financing was necessary; no assurance was given it could be raised on acceptable terms. Failure could require reduced operations, asset sales or cessation of operations.
- COVID-19: Canadian authorized clinics closed, commercial activity was affected, and reopening timing was uncertain. Clinical research, regulatory submissions, suppliers and access to capital could also be disrupted. The planned TBI-002 mmTBI trial was temporarily suspended; before the pandemic, enrollment was expected to begin in April 2020, with trial completion and an FDA submission targeted for Q2 2021. The company said it was evaluating restart timing.
- Regulatory outlook: Helius planned to pursue U.S. clearance for the MS indication and expected to submit to the FDA in H2 2020. Its prior mmTBI de novo application was denied in April 2019; a redesigned 103-subject trial was intended to address FDA feedback. The EU application had been withdrawn, and the company said it would reconsider submission when conditions stabilized.
- Nasdaq listing: The company received a minimum-bid-price deficiency notice. Nasdaq tolling related to COVID-19 moved the stated deadline to December 3, 2020. Delisting could impair share liquidity and the company’s ability to raise capital.
- Other matters: Two related putative shareholder class actions alleged misleading statements about FDA approval prospects; the company disputed the claims and could not predict outcomes. A $323,000 PPP loan was received after quarter end; the company stated it intended to return the proceeds based on subsequent federal guidance, subject to further guidance. The filing describes a $2.0 million contractual penalty related to U.S. government availability of PoNS, but says the amended obligation had been met and payment was remote.
Most important facts for investors to verify
- Confirm the issuer: this source is Helius Medical Technologies, Inc., not Solana Co.
- Assess near-term cash needs against the stated Q2 2020 funding horizon, operating cash burn and going-concern disclosure; verify subsequent financing and cash developments.
- Track the impact of clinic closures and the timing of PoNS commercialization, reimbursement and clinical-trial activity.
- Verify progress on the planned FDA MS submission and TBI-002 trial, along with the status of Australian review and Canadian sales.
- Review dilution from the March offering, warrants and future ATM sales, and monitor Nasdaq bid-price compliance.
- Follow the shareholder litigation and the intended return or final treatment of the PPP loan.